Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
TDap vaccine (Boostrix) was inadvertently given to a newborn baby; This non-serious case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a neonate patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 16-JAN-2025, the patient received Boostrix. On 16-JAN-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: TDap vaccine (Boostrix) was inadvertently given to a newborn baby). The outcome of the inappropriate age at vaccine administration was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 16-JAN-2025 The physician reported that on the day of reporting a TDap vaccine (Boostrix) was inadvertently given to a newborn baby which led to, inappropriate age at vaccine administration. According to reporter, the patient was not even one-day old. The reporter did not agree additional details on the patient when asked. The Vaccine Administration Facility was the same as Primary Reporter.